Skip to main content

Table 2 Univariate survival analysis of OS and DFS in patients with endometrial endometrioid adenovarcinoma

From: RRBP1 overexpression is associated with progression and prognosis in endometrial endometrioid adenocarcinoma

Variables

n

OS

P a

DFS

P a

Mean ± SE(month)

95% CI

Mean ± SE(month)

95% CI

Age(years)

 <60

93

77 ± 2

74–80

P = 0.872

74 ± 2

70–78

P = 0.695

  ≥ 60

37

75 ± 2

72–79

 

74 ± 2

69–78

 

FIGO stage

 I

103

78 ± 1

75–80

P <0.001

76 ± 1

73–79

P <0.001

 II

17

76 ± 3

70–82

 

72 ± 4

64–80

 

 III

10

52 ± 3

46–58

 

45 ± 5

35–54

 

Histological grade

 G1

42

78 ± 2

73–82

P = 0.593

78 ± 2

74–83

P = 0.160

 G2~ G3

88

75 ± 1

74–79

 

71 ± 2

67–75

 

Lymph node metastasis

 No

122

78 ± 1

75–80

P <0.001

77 ± 1

74–80

P <0.001

 Yes

8

51 ± 4

44–58

 

40 ± 5

30–50

 

Deep muscular layer infiltration

 <50%

107

78 ± 1

76–81

P = 0.001

77 ± 2

74–80

P = 0.002

  ≥ 50%

23

66 ± 3

60–72

 

61 ± 4

53–69

 

RRBP1

 Low expression

55

82 ± 1

81–84

P = 0.001

82 ± 1

81–84

P <0.001

 High expression

75

72 ± 2

74–79

 

68 ± 2

72–78

 
  1. FIGO, International Federation of Gynecology and Obstetrics; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; RRBP1, Ribosome-binding protein 1; OS, overall survival; DFS, disease-free survival; aLog-rank test